Positive results in the ChronSeal®-study

​

As was made public earlier the multi-center study conducted in Sweden and Norway on ChronSeal® for the treatment of chronic leg wounds is now completed. In the study two dose concentrations were compared with placebo. Precise results of the study may not be disclosed to the public yet in consideration of ongoing licensing discussions with a potential license-candidate, who has the contractual privilege to the study results. However, we can report that a positive effect on the healing of the wounds was obtained in those patients receiving active drug. No drug related serious adverse events were reported.  Studies are now being planned for finding the optimal dose and treatment duration for obtaining the best treatment results.

“We are very pleased with the positive outcome of the ChronSeal® study. Of course we are sorry that we cannot disclose the precise results just yet, however, it is more important for ChronTech that the discussions with our potential partner continues smoothly” says Anders Vahlne, CEO of ChronTech Pharma.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.